Open terminalDashboard

Last updated Nov 13, 7:00 AM ET · 1 update

Merck Says EU Panel Backs Wider Use of RSV Shot Enflonsia

Merck said an EU drug regulator's expert panel backed expanding approval of its RSV shot Enflonsia to more young children.

More on this company

  1. Merck said on Friday that the European Medicines Agency's scientific advisory panel issued a favorable recommendation to broaden the approved use of its antibody treatment Enflonsia (clesrovimab), according to a Business Wire release from the company.

What happened

Merck announced, per Business Wire, that European regulators' expert advisory group has recommended widening the approved patient group for Enflonsia, an antibody shot meant to guard against respiratory syncytial virus (RSV). The company said the expanded recommendation would cover toddlers heading into their second season of RSV exposure, extending protection beyond the first year of life. Business Wire reported the announcement came from Merck's Rahway, New Jersey headquarters on the morning of November 13, 2026.

How the stock has moved

MRK traded at $147.12 in pre-market trading, up 0.12% since Thursday's close of $146.95, which is also its level since the news was first reported.

Merck & Co. (MRK) since the news
MeasureValue
Price, pre-market trading$147.12
Since the close before the first report (Thursday, November 12, 2026)+0.12%
Change from the close on Thursday, November 12, 2026+0.12%
Market value at the close on Thursday, November 12, 2026$362.27 billion

Source: Stock quote; the close before the first report from our saved closes · as of November 13, 2026 at 7:00 AM ET · Shows what the stock did after the news was first reported, not why.

Its suppliers and customers

Three suppliers tied to Merck in company filings — Verona Pharma, Sidera Therapeutics and Doctor Fultz Pharma — are all unlisted and have shown no trading activity since their last recorded close.

Suppliers and customers of Merck, and how they are trading
CompanyRoleStockSince last close
Verona PharmaSupplierNot listed—
Sidera TherapeuticsSupplierNot listed—
Doctor Fultz PharmaSupplierNot listed—

Source: Relationships named in company filings (Earnings call transcript); stock quotes · as of November 13, 2026 at 7:00 AM ET · A supplier or customer moving the same day is not evidence that one move caused the other.

Sources

  • — Business Wire

How this was made

Written from WiseView data and the sources credited above, and reviewed by an editor before it went up. It is updated as new reports come in, and every update is checked before it goes up. How this report is made

For information only, not investment advice.

More from the desk

Follow MRK in the terminal.

Every panel, HootAI, the squawk and the pre-market board, on one membership.

Annual

$83/mo

Billed annually, $997 once a year.

Monthly

$127/mo

Billed monthly. Cancel any time.

14-day free trial · no card needed · nothing to cancel. Buying for a team? Seats on one invoice.